ArticleUnited European gastroenterology journal2019
CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease.
Article in United European gastroenterology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02464150 (Gluten Challenge in Celiac Disease), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gluten Challenge in Celiac Disease
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Gastrointestinal and Extraintestinal Symptoms Among Subjects With Celiac Disease Undergoing a Dose-Specified Gluten Challenge: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2026Pooled it
- Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.Gastroenterology · 2021Trial
- A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.Frontiers in immunology · 2021Trial
- Detection of Gliadin-Activated CD4Journal of cellular and molecular medicine · 2025Article
- Celiac Disease-Narrative Review on Progress in Celiac Disease.Foods (Basel, Switzerland) · 2025Review
- An optimised whole blood interleukin-2 release assay is more sensitive than interferon-γ ELISpot for detecting and quantifying gluten-specific CD4Clinical & translational immunology · 2025Article
- Coeliac disease as a model for understanding multiple sclerosis.Nature reviews. Neurology · 2024Review
- Past, Present, and Future of Noninvasive Tests to Assess Gluten Exposure, Celiac Disease Activity, and End-Organ Damage.Gastroenterology · 2024Review
- Tolerance-inducing therapies in coeliac disease - mechanisms, progress and future directions.Nature reviews. Gastroenterology & hepatology · 2024Review
- Shift in the B cell subsets between children with type 1 diabetes and/or celiac disease.Clinical and experimental immunology · 2024Article
- Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Expression of transglutaminase 2 in human gut epithelial cells: Implications for coeliac disease.PloS one · 2023Article
- Targeting CD38 in Neoplasms and Non-Cancer Diseases.Cancers · 2022Review
- Intestinal and blood lymphograms as new diagnostic tests for celiac disease.Frontiers in immunology · 2022Review
- Single-cell approaches to dissect adaptive immune responses involved in autoimmunity: the case of celiac disease.Mucosal immunology · 2022Review
- Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Circulating CD103Mucosal immunology · 2021Article
- Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease.Clinical and experimental immunology · 2021Article
- In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The Evolving Landscape of Biomarkers in Celiac Disease: Leading the Way to Clinical Development.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing efforts are being put into new treatment options for coeliac disease (CeD), a chronic disorder of the small intestine induced by gluten. Interleukin-2 (IL-2) and gluten-specific CD4 + T cells increase in the blood after four hours and six days, respectively, following a gluten challenge in CeD patients. These responses are unique to CeD and are not seen in controls. We aimed to evaluate different markers reflecting a recall response to gluten exposure that may be used to monitor therapy. Methods: CeD patients on a gluten-free diet underwent a one- ( Results: The frequency of gut-homing, tetramer-binding, CD4 + effector memory T (tetramer + β7 + T Conclusions: The optimal time points for monitoring therapy response in CeD after a three-day oral gluten challenge is four hours for plasma IL-2 or six to eight days for the frequency of tetramer + β7 + T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.